Table 2.
Summary of the studies describing pediatric patients with COVID-19 following HCT.
| Study | n (Age Range) | Male, n (%) | Time Since Transplant, (Months) |
Graft | GVHD History, n (%) |
ICU (%) | Deaths (%) |
|---|---|---|---|---|---|---|---|
| (25) | 3 (NR) | NR | 25, 41, 41 | NR | NR | 0 (0%) | 0 (0%) |
| (26) | 1 (0.6) | 0 | 3 | Allo | 1 | NR | 0 (0%) |
| (27) | 3 (NR) | NR | 5–22 | Allo | NR | NR | 0 (0%) |
| (28) | 6 (NR) | NR | NR | NR | NR | 0 (0%) | 0 (0%) |
| (29) | 8 (NR) | NR | NR | NR | NR | NR | 2 (25%) |
| (30) | 1 (15) | 0 | 0.3 | Allo | 0 | 1 (100%) | 0 (0%) |
| (31) | 1 (8) | 1 | NR | Allo | NR | 1 (100%) | 0 (0%) |
| (32) | 1 (8) | 1 | 0.7 | Allo | 0 | NR | 1 (100%) |
| (33) | 1 (17) | 0 | 3 | NR | 1 | NR | 0 (0%) |
| (34) | 1 (5) | 1 | 5 | Allo | 1 | NR | 0 (0%) |
| (35) | 2 (2–17) | 1 | 5, 6 | Allo | 1 (50) | NR | 0 (0%) |
| (36) | 1 (9) | 0 | 0 | Allo | 0 | NR | 0 (0%) |
| (37) | 2 (5,13) | 1 | 2 | Allo | NR | 2 (100%) | 0 (0%) |
| (38) | 4 (3–10) | 3 | 0.6, 13, 15, 16 | Allo | 3 (75) | 1 (25%) | 1 (25%) |
| (39) | 1 (16) | 0 | 5 | Allo | 1 | NR | 0 (0%) |
| (40) | 8 (1–12) | 7 | 1–24 | Allo | 3 (38) | NR | 1 (12.5%) |
| (41) | 4 (NR) | NR | NR | NR | NR | 2 (50%) | 0 (0%) |
| (42) | 6 (1.9–12.6) | 4 | NR | Allo | NR | 0 (0%) | 0 (0%) |
| TOTAL | 54 | 19/30 (63) | 0–24 | 13/13 (100%) | 11/21 (52%) | 7/27 (26%) | 5/54 (9.3%) |
GVHD, graft versus host disease; ICU, intensive care unit; Allo, allogeneic; NR: not reported.